chemotherapy for breast cancer stage 4

... for Breast Cancer 97 4.4.1 Social support 97 4.4.1.1 Peer support 97 Trang 84.4.1.2 Family and friends support 984.4.1.3 Religious support 99 4.4.2 Medical support 99 4.4.2.1 Empathy 99 4.4.2.2 ... Chemotherapy for Breast Cancer .90 4.3.1 Hope 91 4.3.2 Optimism 93 4.3.3 Self-esteem 94 4.3.4 Confidence 95 4.4 Support Systems that Influence Resilience in Women who Completed Chemotherapy for ... Psychological impact 262.4 Personal Traits that Influence Resilience in Women who Completed Chemotherapy for Breast Cancer 30 2.4.1 Hope 31 2.4.2 Optimism 33 2.4.3 Self-esteem 35 2.4.4 Confidence 39 2.5

Ngày tải lên: 31/07/2019, 00:38

... Fig.2) Clinical stage (84% 5-year-PFS for stages I-II and 62% for stage III) (p = 0.00001), TNBC subtype (62% 5-years-PFS,p = 0.00001), and pathological response (72% 5- year-PFS for patients not ... (45) 45.3% (48) p < 0.01 HR+/Her2- 54.5% (120) 21.7% (23) Grade SBR II 51.9% (111) 34% (36) p < 0.01 Clinical stage I-II 68.9% (151) 81.1% (86) p = 0.02 Vitamin D level < 20 ng/mL 45.5% ... response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet Lond Engl 2014;384:164 –72 https://doi.org/10.1016/S0140-6736(13)62422-8 3 von Minckwitz G, Untch M, Blohmer

Ngày tải lên: 03/07/2020, 01:26

... 9370 ± 7724 (4702 –14038) 7847 ± 6479*** 5334 –10359) 13650 ± 9864 (8895 –18404) Pd-MP/PS + (/ μL) 695 ± 361 (550 –1020) 9698 ± 7931 §§ (7649 –11746) 9115 ± 7428 (4626 –13604) 7570 ± 6241*** (5150 ... § (306 –370) ETP (nM.min) 1498 ± 225 (1413 –1581) 1531 ± 337 (1448 –1623) 1626 ± 332 (1424 –1826) 1499 ± 374 (1366 –1656) 1515 ± 285 (1369 –1650) Pd-MP (/ μL) 756 ± 429 (650 –1100) 10015 ± 8223 ... 159 ± 47** (139 –168) 172 ± 55 §* (138 –205) 146 ± 56 § (122 –168) 162 ± 49** (126 –180) Peak (nM) 288 ± 48 (269 –305) 341 ± 65* (323 –365 369 ± 75** (323 –414) 334 ± 90 §§ (301 –371) 343 ± 69

Ngày tải lên: 30/09/2020, 13:32

... postoperative) chemotherapy for locally advanced gastric cancer [3] Up to this point, many neoadjuvant chemotherapy treatments for gastric cancer have been used with varying success to downstage locally ... 84 patients (76%), 1 patient (1%) and 4 patients (4%) received one, two, three, four, five or six cycles, respectively, of chemotherapy before surgery No dose reduction was required in the 410 ... receiving neoadjuvant chemotherapy for gastric cancer If neoadjuvant chemotherapy is to be considered as a therapeutic option in patients with locally advanced gastric cancer, it is necessary

Ngày tải lên: 09/08/2014, 02:21

... This effect was more evident in 4T1 cells, which showed a fall in viability of 46% (± 2.7), 69% (± 2), and 74% (± 1.4) after Magh-Rh (H cit) treatment for 24, 48, and 72 h, respectively Within ... Lip-Magh-Rh2(H2cit)4treatment decreased 4T1 cell viability by 57% (± 1.3), 68% (± 2.4), and 84% (± 2.9) after 24, 48 and 72 h treatments, respectively (Figure 9) In contrast, the same dose of free Rh2(H2cit)4 ... Rh2(H2cit)4 to magnetic nanoparti-cles induced specific cytotoxic effect in carcinoma cells Therefore, we suggest that Magh-Rh2(H2cit)4 and Lip-Magh-Rh2(H2cit)4 may be explored as potential drugs for chemotherapy

Ngày tải lên: 11/08/2014, 00:23

... treatment regimens for breast cancer remain unsatisfactory The relapse rate for breast cancer patients is 85% (Bernard-Marty, Cardoso et al 2004) This highlights the Trang 24need for the continued ... AND VINCRISTINE43 Trang 43.7 DRUG RELEASE OF STUDIES 45 4.2.1 Effect of cholesterol on quercetin incorporation 49 4.2.2 Effect of incorporation of 5 mol% of DSPE-PEG 2 0 0 0 4.2.3 Influence ... range of cancers such as colon cancer (van der Woude, Gliszczynska-Swiglo et al 2003), breast cancer (Hakimuddin, Paliyath et al 2004), ovarian cancer (Ferry, Smith et al 1996), prostate cancer

Ngày tải lên: 11/09/2015, 10:07

... countries concerning prevalence (24.4 in males and 14.6 in females) as well as mortality (14.0 per 100,000 of population) [2] The 5-year survival rate for gastric cancer is only around 20-30% worldwide, ... DISCUSSION Neo-adjuvant chemotherapy is indicated as a "down-staging" approach to advanced gastric cancer that aims to increase the ability to perform radical surgery For high-risk cases ... Nations (ASEAN) Asian Pac J Cancer Prev, 13(2), 411-20. 30(6), 643-9. 4 Japanese Gastric Cancer Association Registration C, Maruyama K, Kaminishi M, et al (2006) Gastric cancer treated in 1991 in

Ngày tải lên: 09/01/2020, 14:50

... 220 (64.0) 153 (44.6) Yes 314 (45.7) 143 (41.7) 171(49.7) 124 (36.0) 190 (55.4) No 535 (77.9) 267 (77.8) 268 (77.9) 252 (73.3) 283 (82.5) Single-agent 166 (24.2) 89 (25.9) 77 (22.4) 84 (24.4) 82 ... 373 (54.3) 107 (64.5) 266 (51.1) 148 (62.7) 72 (61.0) 76 (64.4) Yes 314 (45.7) 59 (35.5) 255 (48.9) 88 (37.3) 46 (39.0) 42 (35.6) No 535 (77.9) 130 (78.3) 405 (77.7) 171 (72.5) 89 (75.4) 82 (69.5) ... 87 (52.4) 296 (56.8) 116 (49.2) 56 (47.5) 60 (56.8) Recurrent 304 (44.3) 79 (47.6) 225 (43.2) 120 (50.8) 62 (52.5) 58 (49.2) Well, moderate 167 (24.3) 50 (30.1) 117 (22.5) 67 (28.4) 34 (28.8)

Ngày tải lên: 17/06/2020, 03:27

... [53] The most common wavelength used was 904 nm, reported in 6/11 studies [46, 48–50, 54, 55], three studies used a combination of two wavelengths [44, 45, 51], and one study failed to report the ... improvements in early detection, diagnosis, and treatment of breast cancer, as well as an increase in breast cancer incidence, the number of breast cancer survivors is growing [1] It is estimated that ... (Photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review Abstract Background: Breast cancer related lymphedema (BCRL) is a prevalent complication secondary to cancer treatments

Ngày tải lên: 06/08/2020, 03:41

... miR-1908-3p in breast cancer included ID4, LTBP4, GPM6B, RGMA, EFCAB1, ALX4, OSR1 and PPARA Higher expression of these eight genes correlated with a better prognosis for breast cancer patients ... MiR-1908-3p is highly expressed in breast cancer tissues and breast cancer cells a The miR-1908-3p expression level in breast cancer tissues and adjacent normal breast tissues were compared using ... with down-regulated mRNAs in breast cancer samples These genes were ID4 (inhibitor of DNA binding 4), LTBP4 (latent transforming growth factor beta binding protein 4), CCNB1IP1 (cyclin B1 interacting

Ngày tải lên: 06/08/2020, 05:32

... prognosis in breast cancer Breast Cancer Res 2014;16(6):486. 18 Bertucci F, Finetti P, Birnbaum D The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy. ... Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast Cancer 1994;73(2):362 –9. 4 Schott AF, Hayes DF Defining the benefits of neoadjuvant chemotherapy for ... expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients Breast Cancer Res Treat 2008; 108(2):233 –40. 14 Knauer M, Mook S,

Ngày tải lên: 06/08/2020, 07:53

... dataset GSE1456 are two online breast cancer datasets with radiotherapy information [24, 25] Both of the two datasets with their supplementary clinical infor-mation were downloaded and used for validating ... and mortality rate of breast cancer are still raising [1] In 2013, breast can-cer accounted for 25 % of total cancan-cer cases and 15 % of cancer-related deaths worldwide [1] For decades, surgi-cal ... Trang 2Breast cancer is the most frequently diagnosed cancer among females worldwide [1] In more developed coun-tries like the U.S., breast cancer death rates have slowly decreased by 1.4 % per

Ngày tải lên: 20/09/2020, 17:57

... 1744 755 (43.3 %) 41.4 % 2004 –2007 2129 964 (45.3 %) 41.2 % 2008 –2011 2263 935 (41.3 %) 38.9 % Age at diagnosis Tumor size (mm) ER status Negative 2316 1037 (44.8 %) 43.5 % Positive 4254 1854 ... 5029 2062 (41.0 %) 39.2 % Country Malaysia 3274 1460 (44.6 %) 43.0 % Singapore 3533 1510 (42.7 %) 38.5 % Period of diagnosis 1990 –1994 124 58 (46.8 %) 52.0 % 1995 –1999 547 258 (47.2 %) 41.9 % 2000 ... Positive 4254 1854 (43.6 %) 38.5 % PR status Negative 2656 1195 (45.0 %) 42.1 % Positive 3507 1511 (43.1 %) 38.5 % Her2 status Negative 2872 1197 (41.7 %) 39.2 % Equivocal 429 182 (42.4 %) 39.2 % Positive

Ngày tải lên: 20/09/2020, 18:20

... negative in 14 studies, exclusively positive in 1 study, mixed in 4 studies, and not clear in 4 studies (Table 1) In the sub-group of 14 studies with clinically node-negative breast cancer, the ... 0.44–1.29, P > 0.05) Conclusions: Although the combination of blue dye and radioisotope outperformed radioisotope alone in SLN detection, the superiority for dual tracers may be limited for ... se-lected for meta-analyses [1, 3, 8, 10–12, 17–34] The flow diagram of selection process was depicted in Fig 1 Study characteristics and quality assessment A total of 15,462 patients with breast cancer

Ngày tải lên: 21/09/2020, 11:38

... standard of care for breast cancer at that time Unfortunately, the molecular subtype of breast cancer (e.g., triple negative, HER2+, HR+) was not available for the active patient or breast cancer survivor ... radiation/chemotherapy treatment Out-comes for the active breast cancer treatment group were compared to breast cancer survivors (at least a year out of treatment) enlisted from a breast-cancer ... average for all items) 26 1.49 25 20 1.58 44 Trang 9Table 3 Partial correlation coefficients for questionnaire measures for active treatment patientsPartial Correlation Coefficients – Controlling for

Ngày tải lên: 23/09/2020, 01:22

... [40,46,47], orgasmic disdis-order [48,49], sexual pain [50,51], and vaginismus [52,53] Several modified treatment programs have been developed and evaluated for breast cancer survivors [44,54] ... histologically confirmed breast cancer (stages: T1-T4, N0-N1 and M0); (3) a diag-nosis of breast cancer six months to five years prior to study entry; (4) completion of breast cancer treatment (with ... functioning in young breast cancer survivors Cancer 2014;120(15):2264 –71. 16 Avis NE, Crawford S, Manuel J Psychosocial problems among younger women with breast cancer Psychooncology 2004;13(5):295 –308.

Ngày tải lên: 29/09/2020, 16:10

... C12292/ A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - ... differential model performance Breast Cancer Res 2012;14(6):R144. 3 Ripperger T, Gadzicki D, Meindl A, Schlegelberger B Breast cancer susceptibility: current knowledge and implications for genetic counselling ... SNPs A B A Results on Taqman genotypes for 1362 breast cancer cases and 1514 controls included in the GWAS. B Results on Taqman genotypes for all 1563 breast cancer cases and 2981 controls. *n.a

Ngày tải lên: 30/09/2020, 10:53

... cases of breast cancer samples, suggests, similar to other cancer types, that a low expression of RECK indi-cates a shorter survival rate for patients with invasive breast cancer [24] The available ... (16.6 %) 160 (15.7 %) 0.243 0.6222 Positive (N1, N2, N3) 341 (33.5 %) 348 (34.2 %) Recurrence ER/PR status Histological grade TNM stage 3A, 3B, and 3C 240 (23.2 %) 240 (23.2 %) χ2, Chi-square ... prognostic information for breast cancer patient survival (Tables 2 and 3), strengthening the already reported evidence that this MMP inhibitor is not a relevant biomarker for breast cancer Discussion

Ngày tải lên: 30/09/2020, 11:02

... Stage Left 0.9483 II 147 (52.5) 73 (26.1) 74 (26.5) III 90 (32.1) 42 (15.0) 48 (17.2) IV 29 (10.4) 13 (4.7) 16 (5.7) Stage Right 0.0945 I 26 (10.2) 15 (5.9) 11 (4.4) II 123 (48.2) 67 (26.4) 56 (22.1) ... Am J Epidemiol 2008, 168(4):404 –411. 23 Euhus DM: Understanding mathematical models for breast cancer risk assessment and counseling Breast J 2001, 7(4):224 –232. 24 van Asperen CJ, Jonker MA, ... 11(6):457 –464. 33 Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 2003, 362(9382):419 –427. 34 Collaborative-Group-on-Hormonal-Factors-in-Breast-Cancer: Breast

Ngày tải lên: 30/09/2020, 14:41

... 36.7% (2784/ 7580) and 43.6% (1938/4445) of patients received adju-vant chemotherapy, and 84.3% (6373/7556) and 54.6% (2417/4422) of patients underwent adjuvant hormonal therapy for the G3S cohort ... (Figure 2) In the IPC cohort, the proportion of patients eligible for TARGIT was 8% (356/4445) and 33.9% (1509/4445), respectively, for the criteria of the RIOP and TARGIT A trials Survival without ... years was 98% and 97.1%, re-spectively, for the R1E groupversus 97.1% and 94.8% for the R1nE group; 97.6% and 96.4% for the T1E groupversus 97% and 94.2% for the T1nE group There was a significant

Ngày tải lên: 30/09/2020, 15:12